Niki BioSolutions, Inc.
NIKIHealthcareNASDAQBiotechnology · Last scanned Sep 8, 2026
Scan Results
Daily timeframeNiki BioSolutions, Inc., through its subsidiaries, operates as a clinical-stage biopharmaceutical company and engages in the discovery, development, and commercialization of therapeutic products to. Valued at $5.0M, NIKI is a micro-cap name in its sector. Its pipeline products include SACT-1, a repurposed drug candidate, which is in a Phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small molecule, which is in a Phase 1 clinical trial for the treatment of bacterial infections, such as staphylococcus aureus, mycobacterium tuberculosis, and pseudomonas aeruginosa.
Market Cap
$5.0M
Beta
-0.90
P/E (TTM)
—
P/E (Fwd)
—
EPS (TTM)
$-2.90
EPS (Fwd)
—
ROE
-17.1%
ROA
-10.0%
Cash
$1.8M
Total Debt
$3.5M
Free CF
-$1.7M
52W Change
-65.6%
Annual Financials
Cash vs Debt
Where NIKI stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, NIKI finished 23.14% below its 150-day moving average ($8.60) and 29.76% below its 200-day moving average ($9.41). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is NIKI overbought or oversold?
At the September 3, 2026 close, NIKI's RSI(14) was 27.0, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, NIKI has $1.8M in cash with $3.5M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Free cash flow is running at -$1.7M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -17.1% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $1.3M (2022) to $0 (2025), a 100% decline worth watching.
The relatively low beta of -0.90 suggests NIKI is a less volatile holding compared to the broader index. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Niki BioSolutions, Inc.'s trajectory.